Intrexon | XON - Gross Profit On Sales


Intrexon reported $-297K in Gross Profit on Sales for its fiscal quarter ending in June of 2024.





Gross Profit On Sales Change Date
Agenus USD 33.74M 468K Mar/2026
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
Amgen USD 5.87B 1.02B Mar/2026
Anika Therapeutics USD 19.18M 3.6M Dec/2025
Arrowhead Research USD 75.25M 1.52M Jun/2026
AstraZeneca USD 12.86B 251M Jun/2026
Bristol-Myers Squibb USD 9.26B 1.19B Jun/2026
Gilead Sciences USD 6.8B 1.29B Jun/2026
GlaxoSmithKline GBP 6.51B 757M Jun/2026
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Incyte USD 1.57B 400.89M Jun/2026
Intrexon USD -297K 167K Jun/2024
Karyopharm Therapeutics USD 33.72M 1.13M Mar/2026
Ligand Pharmaceuticals USD 100.41M 51.96M Jun/2026
MacroGenics USD 11.24M 19.87M Mar/2026
MannKind USD 7.77M 60.56M Jun/2026
Merck USD 12.09B 1.24B Mar/2026
Novartis USD 11.24B 1.18B Jun/2026
Rigel Pharmaceuticals USD 28.49M 7.01M Jun/2024
Roche Holding CHF 22.69B 600M Jun/2026
Sangamo BioSciences -2.39M 1.09M Jun/2024
Thermo Fisher Scientific USD 4.49B 146M Mar/2026
Veracyte USD 108.55M 7.39M Jun/2026
Xencor USD 51.22M 46.7M Jun/2026